Medinet cuts FY2025 revenue forecast, but expects smaller net loss

Medinet has revised its full-year earnings forecast for September 2025, with projected net sales now 810 million yen, a 120 million yen (12.9%) decrease from the previous forecast of 930 million yen. This adjustment is attributed to the expiration of facility management contracts, lower-than-expected orders for cell processing, and delays in launching new cell processing menus. However, royalty income and new CDMO projects partially offset these declines.

Despite the reduction in net sales, Medinet anticipates an improvement in profitability due to a postponement of R&D expenses and reduced general administrative costs. Operating loss is now projected to be △1,445 million yen, an improvement of 46 million yen from the previous forecast.

Ordinary loss is expected to improve by 146 million yen to △1,339 million yen, driven by favorable investment partnership performance and reversal of allowance for doubtful accounts. Consequently, the net loss for the period is expected to improve by 127 million yen, totaling △1,362 million yen. Earnings per share are now estimated at △5.15 yen.